Anticoagulant Complications in Coronavirus Disease (Covid-19) Patients: Literature Review
Keywords:
Anticoagulation Agents Complications, Anticoagulant Drus Complications, Anticoagulant Complications, COVID-19, COVID-19 Virus Disease, COVID-19 Virus Diseases, COVID-19 Virus Infection, Coronavirus Disease-19, Coronavirus Disease 19Abstract
The most common thrombotic complication in severe COVID-19 patients is venous thromboembolism, following the events of venous and arterial thrombosis are deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction, and systemic arterial embolism. Patients with COVID-19 often have a thrombosis incidence of 31%. Anticoagulation is a therapy to treat thrombosis as a complication of COVID-19. Administration of anticoagulants causes several complications, including bleeding that can cause death. Objective: to determine the complications of anticoagulation in patients with coronavirus disease (COVID-19). Methods: This research was written as a variety of literature with a narrative database analysis method which includes Google Scholar, Pubmed, Research Gate. Results: At the article collection stage, 1,586 titles were obtained from 3 search engines. After screening, the authors found 20 articles discussing anticoagulant complications in patients with coronavirus disease (covid-19). From the data obtained, it can be concluded that most studies show that the use of anticoagulants in COVID-19 patients has minor, major bleeding to death.
References
[1] Algahtani H, Subahi A, Shirah B. 2016. Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Rep Neurol Med 2016:1–6
[2] Al-Hameed FM . 2017. Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome coronavirus. Saudi Medi J 38(2):196–200
[3] Al-Samkari H, et al. 2020. COVID and coagulation: bleeding and thrombotic manifestations of SARSCoV2 infection. Blood. https://doi.org/10.1182/blood.2020006520.
[4] Bunch, C. M, Thomas, A. V, Stillson, J. E. et al. 2021. Preventing thrombohemorrhagic complications of heparinized covid-19 patients using adjunctive thromboelastography: A retrospective study. Journal of Clinical Medicine, 10(14), 1–16. https://doi.org/10.3390/jcm10143097
[5] Chaerub, j. 2021. Terapi Antikoagulan pada COVID-19. CDK-295, 340-342.
[6] Chatphatai Moonla, M. M, et al. 2021. Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 1-12.
[7] dr. Praseno Hadi, P. S, dr. Fathiyah Isbaniah, S. et al . 2020. rekomendasi idi pemberian antikoagulan profilaksis pada pasien covid-19 yang di rawat di rumah sakit. jakarta.
[8] Hamidjoyo, B. P, & Wreksoatmodjo, B. R. 2021. Pengaruh Coronavirus Disease 2019 (COVID-19) terhadap Insidens dan Tatalaksana Penyakit Serebrovaskular. CDK Edisi CME, 283-288.
[9] Hanif, A, et al. 2020. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Annals of Hematology, 2323-2328.
[10] Haren, F. M, et al. 2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. van Haren et al. Critical Care, 1-11.
[11] Hidayani, W. R. 2020. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Riview. Jurnal Untuk Masyarakat Sehat (JUKMAS), 120-134.
[12] Investigators, R.-C., Investigators, A.-4., Investigators, A., EC, G., CA, B., BJ, M., LPG, D. 2021. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The new england journal o f medicine, 385(9), 777–789. https://doi.org/10.1056/nejmoa2103417.
[13] Juanita, R. A. et al. 2021. Penggunaan Low Molecular Weight Heparin untuk Pasien COVID-19 dengan Kehamilan: Studi Literatur. JPSCR: Journal of Pharmaceutical Science and Clinical Research, 339-348.
[14] Klok, F., et al. 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research 191, 143-147.
[15] Marpaung, R., Chandra, E., & Suwanto, D. 2020. Hiperkoagulabilitas pada Kehamilan dengan COVID-19. CDK-290, 713-717.
[16] Meizlish, M. L. et al. 2021. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. MEIZLISH ET AL, 471-479.
[17] Musoke, N., Lo, K. B., Albano, J., Peterson, E., Bhargav, R., Gul, F., .Rangaswami, J. 2020. Anticoagulation and bleeding risk in patients with COVID-19. Thrombosis Research, 225-230.
[18] Priyana, A. 2021. perdarahan iliopsoas pada pasien covid-19 dalam terapi antikoagulan. EBERS PAPYRUS, 116-123.
[19] Rachel P. Rosovsky MD, M., Kristen M. et al. 2020. Anticoagulation practice patterns in COVID-19: A global survey. Res Pract Thromb Haemost, 969–983.
[20] Rico-Mesa, J. S., Rosas, D., Ahmadian-Tehrani, A., White, A., Anderson, A. S., & Chilton, R. 2020. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current Cardiology Reports, 1-6.
[21] Rusdiana, T., & akbar, r. (2020). Perkembangan Terkini Terapi Antikoagulan pada Pasien COVID-19 dengan Gejala Berat. Jurnal Sains Farmasi & Klinis, 244-250.
[22] Sharifian-Dorche, M., et al. 2020. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. Journal of the Neurological Sciences, 1-18.
[23] Shi, l., wang, y., wang, y.-d., duan, g.-c., & yang, h.-y. 2020. D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients. European Review for Medical and Pharmacological Sciences, 8576-8579.
[24] Tandon, R., Sharp, J. et al. 2021. Effective Inhibition of SARS-CoV-2 Entry by Heparin and enoxaparin Derivatives. Journal of Virology, 1-12.
[25] Wardhani, L. F., et al. 2021. Case Report: Heparin-induced thrombocytopenia during COVID-19 outbreak: the importance of scoring system in differentiating with sepsis-induced coagulopathy [version 2; peer review: 2 approved]. F1000Research, 1-11.
[26] Willim, H. A., Hardigaloeh, A. T., Supit, A. I., & Handriyani. 2020. Koagulopati pada Coronavirus Disease-2019 (COVID-19): tinjauan pustaka. intisari sains medis, 749-756.
[2] Al-Hameed FM . 2017. Spontaneous intracranial hemorrhage in a patient with Middle East respiratory syndrome coronavirus. Saudi Medi J 38(2):196–200
[3] Al-Samkari H, et al. 2020. COVID and coagulation: bleeding and thrombotic manifestations of SARSCoV2 infection. Blood. https://doi.org/10.1182/blood.2020006520.
[4] Bunch, C. M, Thomas, A. V, Stillson, J. E. et al. 2021. Preventing thrombohemorrhagic complications of heparinized covid-19 patients using adjunctive thromboelastography: A retrospective study. Journal of Clinical Medicine, 10(14), 1–16. https://doi.org/10.3390/jcm10143097
[5] Chaerub, j. 2021. Terapi Antikoagulan pada COVID-19. CDK-295, 340-342.
[6] Chatphatai Moonla, M. M, et al. 2021. Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 1-12.
[7] dr. Praseno Hadi, P. S, dr. Fathiyah Isbaniah, S. et al . 2020. rekomendasi idi pemberian antikoagulan profilaksis pada pasien covid-19 yang di rawat di rumah sakit. jakarta.
[8] Hamidjoyo, B. P, & Wreksoatmodjo, B. R. 2021. Pengaruh Coronavirus Disease 2019 (COVID-19) terhadap Insidens dan Tatalaksana Penyakit Serebrovaskular. CDK Edisi CME, 283-288.
[9] Hanif, A, et al. 2020. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Annals of Hematology, 2323-2328.
[10] Haren, F. M, et al. 2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. van Haren et al. Critical Care, 1-11.
[11] Hidayani, W. R. 2020. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Riview. Jurnal Untuk Masyarakat Sehat (JUKMAS), 120-134.
[12] Investigators, R.-C., Investigators, A.-4., Investigators, A., EC, G., CA, B., BJ, M., LPG, D. 2021. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The new england journal o f medicine, 385(9), 777–789. https://doi.org/10.1056/nejmoa2103417.
[13] Juanita, R. A. et al. 2021. Penggunaan Low Molecular Weight Heparin untuk Pasien COVID-19 dengan Kehamilan: Studi Literatur. JPSCR: Journal of Pharmaceutical Science and Clinical Research, 339-348.
[14] Klok, F., et al. 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research 191, 143-147.
[15] Marpaung, R., Chandra, E., & Suwanto, D. 2020. Hiperkoagulabilitas pada Kehamilan dengan COVID-19. CDK-290, 713-717.
[16] Meizlish, M. L. et al. 2021. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. MEIZLISH ET AL, 471-479.
[17] Musoke, N., Lo, K. B., Albano, J., Peterson, E., Bhargav, R., Gul, F., .Rangaswami, J. 2020. Anticoagulation and bleeding risk in patients with COVID-19. Thrombosis Research, 225-230.
[18] Priyana, A. 2021. perdarahan iliopsoas pada pasien covid-19 dalam terapi antikoagulan. EBERS PAPYRUS, 116-123.
[19] Rachel P. Rosovsky MD, M., Kristen M. et al. 2020. Anticoagulation practice patterns in COVID-19: A global survey. Res Pract Thromb Haemost, 969–983.
[20] Rico-Mesa, J. S., Rosas, D., Ahmadian-Tehrani, A., White, A., Anderson, A. S., & Chilton, R. 2020. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current Cardiology Reports, 1-6.
[21] Rusdiana, T., & akbar, r. (2020). Perkembangan Terkini Terapi Antikoagulan pada Pasien COVID-19 dengan Gejala Berat. Jurnal Sains Farmasi & Klinis, 244-250.
[22] Sharifian-Dorche, M., et al. 2020. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. Journal of the Neurological Sciences, 1-18.
[23] Shi, l., wang, y., wang, y.-d., duan, g.-c., & yang, h.-y. 2020. D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients. European Review for Medical and Pharmacological Sciences, 8576-8579.
[24] Tandon, R., Sharp, J. et al. 2021. Effective Inhibition of SARS-CoV-2 Entry by Heparin and enoxaparin Derivatives. Journal of Virology, 1-12.
[25] Wardhani, L. F., et al. 2021. Case Report: Heparin-induced thrombocytopenia during COVID-19 outbreak: the importance of scoring system in differentiating with sepsis-induced coagulopathy [version 2; peer review: 2 approved]. F1000Research, 1-11.
[26] Willim, H. A., Hardigaloeh, A. T., Supit, A. I., & Handriyani. 2020. Koagulopati pada Coronavirus Disease-2019 (COVID-19): tinjauan pustaka. intisari sains medis, 749-756.
Downloads
Published
2022-06-30
How to Cite
Afifah, S. Z., & Sulistyani, S. (2022). Anticoagulant Complications in Coronavirus Disease (Covid-19) Patients: Literature Review. Prosiding University Research Colloquium, 165–175. Retrieved from https://repository.urecol.org/index.php/proceeding/article/view/2070
Issue
Section
Articles
License
Copyright (c) 2022 Siti Zulfatul Afifah, S Sulistyani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
